Parthenolide perturbs adenosine transport or metabolism upstream of ADORA2A

ADORA2A neuropharmacology market 49% proposed
Composite
51%
Novelty
67%
Feasibility
61%
Impact
55%
Mechanistic
57%
Druggability
43%
Safety
42%
Confidence
46%

Mechanistic description

Covalent modulation of transporters or metabolic enzymes changes local receptor occupancy in a context-dependent manner.

Evidence for (5)

  • Parthenolide inhibits neuroinflammation via adenosine and A2A receptor signaling.

    PMID:41795299 2025 Phytomedicine

  • Parthenolide ameliorates neurological deficits and neuroinflammation in mice with traumatic brain injury by suppressing STAT3/NF-κB and inflammasome activation.

    PMID:35729839 2022 Int Immunopharmacol

  • Parthenolide, an NF-κB Inhibitor Ameliorates Diabetes-Induced Behavioural Deficit, Neurotransmitter Imbalance and Neuroinflammation in Type 2 Diabetes Rat Model.

    PMID:27553015 2017 Neuromolecular Med

  • Arglabin regulates microglia polarization to relieve neuroinflammation in Alzheimer's disease.

    PMID:35289014 2022 J Biochem Mol Toxicol

  • Parthenolide attenuates LPS-induced fever, circulating cytokines and markers of brain inflammation in rats.

    PMID:22004922 2011 Cytokine

Evidence against (1)

  • Parthenolide promiscuity may make the apparent specificity illusory.

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.